Marksans Pharma Valuation

Q: What is the Fair Price of MARKSANS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

MARKSANS (₹261.3) is trading above our estimate of [[fair value]] (₹197.97)

Is MARKSANS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MARKSANS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MARKSANS (₹261.3) is trading above our estimate of fair value (₹197.97)

Significantly Below Fair Value: MARKSANS is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MARKSANS?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for MARKSANS. This is calculated by dividing MARKSANS's market cap by their current preferred multiple.
What is MARKSANS's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	₹118.41b

MARKSANS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5x
Enterprise Value/EBITDA	23.3x
PEG Ratio	1.7x

Price to Earnings Ratio vs Peers

How does MARKSANS's PE Ratio compare to its peers?

The above table shows the PE ratio for MARKSANS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	68.3x
AETHER Aether Industries	149.5x	45.9%	₹123.5b
531599 FDC	29.7x	n/a	₹88.8b
524742 Caplin Point Laboratories	31.3x	12.5%	₹149.7b
ORCHPHARMA Orchid Pharma	62.6x	43.7%	₹70.2b
MARKSANS Marksans Pharma	35.5x	20.8%	₹118.4b

Price-To-Earnings vs Peers: MARKSANS is good value based on its Price-To-Earnings Ratio (35.5x) compared to the peer average (68.3x).

Price to Earnings Ratio vs Industry

How does MARKSANS's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.8%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	17.8%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: MARKSANS is good value based on its Price-To-Earnings Ratio (35.5x) compared to the Indian Pharmaceuticals industry average (40.4x).

Price to Earnings Ratio vs Fair Ratio

What is MARKSANS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MARKSANS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	35.5x
Fair PE Ratio	39.8x

Price-To-Earnings vs Fair Ratio: MARKSANS is good value based on its Price-To-Earnings Ratio (35.5x) compared to the estimated Fair Price-To-Earnings Ratio (39.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is lower than the current share price.